New Medicare Part D Rule, DIR Fees Highlight SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Mylan Introduces New Triple Combo Once-Daily HIV Treatment
Mylan recently announced the introduction of its FDA-approved triple combination once-daily HIV treatment, efavirenz, lamivudine, and tenofovir disoproxol fumarate (Symfi), in the United States.
4. Ultrasound Technology Could Enhance Cancer Drug Therapies
A new technology called acoustic cluster therapy may make ultrasound useful in cancer treatment.
3. CAR T-Cell Therapies, Biosimilars May Accelerate Push Towards Alternative Payment Models
As innovative, costly products emerge, such as CAR T-cell therapies and biosimilars, payers may be more likely to make the move towards alternative payment models.
2. Study: Striking Differences in Billing Complexity Across Health Insurers
Billing complexity among US health insurers varies significantly, with surprising results in the level of complexity among some insurers.
1. Point-of-Sale DIR Fees Addressed in New Medicare Part D Rule
The Centers for Medicare and Medicaid Services issued a final 2019 Medicare Part D rule on Monday addressing direct and indirect remuneration (DIR) fees.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
